XO Life, the Munich-based patient-pharma platform, has closed a €4 million funding round led by Fil Rouge Capital, with participation from existing investors Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital. 

The investment aims to drive the company toward its Series A, meeting the rising market demand for a unified digital infrastructure that connects patients, healthcare professionals, and pharmaceutical companies. 

The Frontiers Health Connection 

XO Life has been a part of our ecosystem since Frontiers Health 2022 in Milan. During that edition, Co-Founder and CEO Dr. Friderike Bruchmann pitched during the Start-up Discovery session (watch the session here). 

Bruchmann’s presentation focused on XO Life’s "meta-clinical" approach, designed to replace fragmented, siloed apps with a standardized global framework for patient support. Martin Kelly, who moderated the session, noted the technical maturity of the solution: "Great pitch, really well presented. Clearly, you've developed a very sophisticated platform." 

Date: 7 April 2026. 

Source: www.sandwater.com